Additionally, antidiabetic medications—including pioglitazone, GLP-1 receptor agonists (e.g., liraglutide, semaglutide) [86], and SGLT2 inhibitors [87]—have demonstrated efficacy in reducing hepatic fat and improving insulin resistance. The gene discussed is SLC5A2; the disease is Insulin resistance.